WO2007058482A1 - Inhibiteurs de la proteine kinase - Google Patents

Inhibiteurs de la proteine kinase Download PDF

Info

Publication number
WO2007058482A1
WO2007058482A1 PCT/KR2006/004822 KR2006004822W WO2007058482A1 WO 2007058482 A1 WO2007058482 A1 WO 2007058482A1 KR 2006004822 W KR2006004822 W KR 2006004822W WO 2007058482 A1 WO2007058482 A1 WO 2007058482A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine
methyl
thiazolo
amino
ylamino
Prior art date
Application number
PCT/KR2006/004822
Other languages
English (en)
Inventor
Seung-Hyun Yoon
Hyun Woo Joo
Jeong Uk Song
Young Kwan Kim
Sun-Young Koo
So Yeun Yang
Kyoung-Hee Kim
Jin-A Hwang
Heung Soo Cho
Hwan Geun Choi
Dongchul Lim
Ji Soo Song
Hae-Seong Yoon
Sang-Yong Hong
Min-Jeong Kim
Seihyun Choi
Kiwon Jo
Min-Hyeung Kim
Jieun Kim
Jung In Kim
Tae Kyo Park
Original Assignee
Lg Life Sciences, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences, Ltd. filed Critical Lg Life Sciences, Ltd.
Publication of WO2007058482A1 publication Critical patent/WO2007058482A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

L'invention porte sur des composés permettant d'inhiber des kinases de tyrosine du récepteur d'angiogenèse, notamment l'activité de la kinase 2 (« KDR ») du récepteur VEG et sur des procédés de préparation et d'utilisation afférents. L'invention porte également sur des compositions pharmaceutiques les renfermant en une dose thérapeutiquement efficace. Les composés selon l'invention sont utiles pour traiter et prévenir des maladies provoquées par une activité KRD non désirée, notamment des maladies liées à l'angiogenèse, telles que des cancers, le psoriasis, la polyarthrite rumatoïde, la rétinopathie diabétique, etc.
PCT/KR2006/004822 2005-11-16 2006-11-15 Inhibiteurs de la proteine kinase WO2007058482A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050109398 2005-11-16
KR10-2005-0109398 2005-11-16

Publications (1)

Publication Number Publication Date
WO2007058482A1 true WO2007058482A1 (fr) 2007-05-24

Family

ID=38048832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/004822 WO2007058482A1 (fr) 2005-11-16 2006-11-15 Inhibiteurs de la proteine kinase

Country Status (2)

Country Link
KR (1) KR20070052207A (fr)
WO (1) WO2007058482A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117381A2 (fr) * 2006-03-24 2007-10-18 Array Biopharma Inc. Activateurs de glucokinase
WO2010064611A1 (fr) 2008-12-01 2010-06-10 武田薬品工業株式会社 Composé hétérocyclique et applications
WO2010064722A1 (fr) 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Dérivés de benzothiazole convenant comme agents anticancéreux
JP2010527909A (ja) * 2007-06-05 2010-08-19 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
WO2012035055A1 (fr) * 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8853409B2 (en) 2007-09-21 2014-10-07 Array Biopharma Inc. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2016029218A1 (fr) * 2014-08-22 2016-02-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dérivés de 1-aryléthyl-4-acylaminopipéridine substitués à titre de modulateurs des récepteurs d'opioïdes/adrénorécepteur alpha et leur procédé de préparation
US20160347767A1 (en) * 2010-11-19 2016-12-01 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306874B1 (en) * 1999-10-19 2001-10-23 Merck & Co., Inc. Tyrosine kinase inhibitors
US6699863B1 (en) * 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6878720B2 (en) * 1998-11-10 2005-04-12 Novartis Ag VEGF receptor tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878720B2 (en) * 1998-11-10 2005-04-12 Novartis Ag VEGF receptor tyrosine kinase inhibitors
US6306874B1 (en) * 1999-10-19 2001-10-23 Merck & Co., Inc. Tyrosine kinase inhibitors
US6699863B1 (en) * 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMINO N. ET AL.: "YM-231146 A novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors", BIOL. PHARM. BULL., vol. 28, no. 11, 11 November 2005 (2005-11-11), pages 2096 - 2101, XP008081105 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117381A2 (fr) * 2006-03-24 2007-10-18 Array Biopharma Inc. Activateurs de glucokinase
WO2007117381A3 (fr) * 2006-03-24 2008-02-14 Array Biopharma Inc Activateurs de glucokinase
US8883828B2 (en) 2006-03-24 2014-11-11 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
US8354540B2 (en) 2006-03-24 2013-01-15 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
EP2543667A1 (fr) * 2006-03-24 2013-01-09 Array Biopharma, Inc. Analogues de 2-aminopyridine en tant qu'activateurs de la glucokinase
US8022223B2 (en) 2006-03-24 2011-09-20 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
AU2007235558B2 (en) * 2006-03-24 2011-12-01 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
JP2010527909A (ja) * 2007-06-05 2010-08-19 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9079890B2 (en) 2007-09-21 2015-07-14 Array Biopharma Inc. Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives
US8853409B2 (en) 2007-09-21 2014-10-07 Array Biopharma Inc. Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5579619B2 (ja) * 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2010064611A1 (fr) 2008-12-01 2010-06-10 武田薬品工業株式会社 Composé hétérocyclique et applications
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
WO2010064722A1 (fr) 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Dérivés de benzothiazole convenant comme agents anticancéreux
US8497274B2 (en) 2008-12-02 2013-07-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2012035055A1 (fr) * 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
US20160347767A1 (en) * 2010-11-19 2016-12-01 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US10030034B2 (en) * 2010-11-19 2018-07-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
CN108864151A (zh) * 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
US11773110B2 (en) 2010-11-19 2023-10-03 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
WO2016029218A1 (fr) * 2014-08-22 2016-02-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dérivés de 1-aryléthyl-4-acylaminopipéridine substitués à titre de modulateurs des récepteurs d'opioïdes/adrénorécepteur alpha et leur procédé de préparation
US9765027B2 (en) 2014-08-22 2017-09-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
US10617681B2 (en) 2014-08-22 2020-04-14 Arizona Board Of Regents On Behalf Of The University Of Arizona 1-arylalkyl-4-acylaminopiperidine compounds
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
US11858938B2 (en) 2015-03-16 2024-01-02 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof

Also Published As

Publication number Publication date
KR20070052207A (ko) 2007-05-21

Similar Documents

Publication Publication Date Title
WO2007058482A1 (fr) Inhibiteurs de la proteine kinase
JP7105781B2 (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
JP4035559B1 (ja) 酸分泌抑制薬としての１−ヘテロシクリルスルホニル、２−アミノメチル、５−（ヘテロ−）アリール置換１−ｈ−ピロール誘導体
RU2332412C2 (ru) Производные пиразола
CA2794801C (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
US20050014942A1 (en) Amide derivatives and drugs
JP4667537B2 (ja) アシルチオウレア化合物又はその塩、及びその用途
US20040014744A1 (en) Substituted pyridines having antiangiogenic activity
CN112552295A (zh) Kras突变蛋白抑制剂
WO2019149922A1 (fr) Composés qui provoquent la dégradation de l'egfr, destinés à être utilisés contre le cancer
JP6896701B2 (ja) イミダゾリルアミド誘導体
CN113286794A (zh) Kras突变蛋白抑制剂
WO2004080966A1 (fr) Derives heterocycliques renfermant de l'azote et medicaments contenant ces derives comme principe actif
CA2760061A1 (fr) Compose de carboxamide heterocyclique diamino
ZA200407665B (en) New compounds.
JP2013139459A (ja) 化学化合物
JP2009532475A (ja) ヤヌスキナーゼの阻害剤として有用なデアザプリン
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
CN111406054B (zh) 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
JP2009520791A (ja) 酵素阻害剤
WO2012044090A2 (fr) Nouveau composé d'aminoquinazoline possédant une action inhibitrice de la protéine kinase
PT2142533E (pt) Derivados de imidazolidinona
AU2004273771B2 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
CA3172387A1 (fr) Composes a base d'indazole et procedes d'utilisation associes
CN103080086B (zh) 抑制前列腺素d合成酶的哌啶化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847382

Country of ref document: EP

Kind code of ref document: A1